Caregivers of children with HIV in Botswana prefer monthly IV Broadly Neutralizing Antibodies (bNAbs) to daily oral ART
PLOS ONE · 27.03.2024 · 19 (3) · e0299942
DOI: 10.1371/journal.pone.0299942 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift PLOS ONE, online erschienen am 27.03.2024. Verfasst von Maureen Sakoi-Mosetlhi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana. Hauptthemen laut MEDLINE: HIV Infections, HIV-1. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Introduction
Monthly intravenous infusion of broadly neutralizing monoclonal antibodies may be an attractive alternative to daily oral antiretroviral treatment for children living with HIV. However, acceptability among caregivers remains unknown.
Methods
We evaluated monthly infusion of dual bNAbs (VRCO1LS and 10–1074) as a treatment alternative to ART among children participating in the Tatelo Study in Botswana. Eligible children aged 2–5 years received 8–32 weeks of bNAbs overlapping with ART, and up to 24 weeks of bNAbs alone as monthly intravenous infusion. Using closed-ended questionnaires, we evaluated caregiver acceptability of each treatment strategy prior to the first bNAb administration visit (pre-intervention) and after the completion of the final bNAb administration visit (post-intervention).
Results
Twenty-five children completed the intervention phase of the study, and acceptability data were available from 24 caregivers at both time points. Responses were provided by the child’s mother at both visits (60%), an extended family member at both visits (28%), or a combination of mother and an extended family member (12%). Caregiver acceptance of monthly bNAb infusions was extremely high both pre-and post-intervention, with 21/24 (87.5%) preferring bNAbs to ART pre-intervention, and 21/25 (84%) preferring bNAbs post-intervention. While no caregiver preferred ART pre-intervention, 2/25 preferred it post-intervention. Pre-intervention, 3 (13%) caregivers had no preference between monthly bNAbs or daily ART, and 2 (8%) had no preference post-intervention. Pre-intervention, the most common reasons for preferring bNAbs over ART were the perception that bNAbs were better at suppressing the virus than ART (n = 10) and the fact that infusions were dosed once monthly compared to daily ART (n = 9). Post-intervention, no dominant reason for preferring bNAbs over ART emerged from caregivers.
Conclusions
Monthly intravenous bNAb infusions were highly acceptable to caregivers of children with HIV in Botswana and preferred over standard ART by the majority of caregivers. Clinical Trial Number NCT03707977 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
- Harvard Medical School, Boston, Massachusetts, United States of America.
- Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
- Departments of Internal Medicine and Pediatrics, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
- Ragon Institute of Mass General, MIT, and Harvard, Cambridge, Massachusetts, United States of America.
- Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
ORCID-Profile: Maureen Sakoi-Mosetlhi, Gbolahan Ajibola
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Sakoi-Mosetlhi, M., Ajibola, G., Haghighat, R., Batlang, O., Maswabi, K., Pretorius-Holme, M., Powis, K. M., Lockman, S., Makhema, J., Litcherfeld, M., Kuritzkes, D. R., & Shapiro, R. (2024). Caregivers of children with HIV in Botswana prefer monthly IV Broadly Neutralizing Antibodies (bNAbs) to daily oral ART. PLOS ONE, 19(3), e0299942. https://doi.org/10.1371/journal.pone.0299942
Vancouver
Sakoi-Mosetlhi M, Ajibola G, Haghighat R, Batlang O, Maswabi K, Pretorius-Holme M, et al. Caregivers of children with HIV in Botswana prefer monthly IV Broadly Neutralizing Antibodies (bNAbs) to daily oral ART. PLOS ONE. 2024;19(3):e0299942. doi:10.1371/journal.pone.0299942
BibTeX
@article{SakoiMosetlhi2024,
author = {Sakoi-Mosetlhi, Maureen and Ajibola, Gbolahan and Haghighat, Roxanna and Batlang, Oganne and Maswabi, Kenneth and Pretorius-Holme, Molly and Powis, Kathleen M and Lockman, Shahin and Makhema, Joseph and Litcherfeld, Mathias and Kuritzkes, Daniel R and Shapiro, Roger},
title = {Caregivers of children with HIV in Botswana prefer monthly IV Broadly Neutralizing Antibodies (bNAbs) to daily oral ART},
journal = {PLOS ONE},
year = {2024},
volume = {19},
number = {3},
pages = {e0299942},
doi = {10.1371/journal.pone.0299942}
}
EUVIMED